Raza Bokhari Email & Phone Number

Philadelphia, PA, US

Raza currently serves as the Managing Partner of RBx Capital, LP, a private equity fund in formation that is focused on investing in all segments of the US Medical Laboratory testing market, including pharmacogenomics enabled personalized medicine.The fund is positioned to raise $200 million.

Parkway Clinical Laboratories (PCL) is a College of American Pathologists (CAP) accredited national CLIA-certified clinical reference laboratory performing routine and esoteric diagnostic testing. PCL is focused primarily on serving addiction and pain management specialists as well as supporting anti-aging and wellness providers in the initial diagnosis.

Toronto, Ontario, CA

Toronto, Ontario, CA

Toronto, Ontario, CA

Toronto, Ontario, CA

• In 2008 became one of the largest individual stockholder of the company behind the founders and institutional investors.
• Led the establishment of Rosetta’s global commercial operation in Philadelphia

• Acquired financially distressed company in 2003.
• Invested more the $1.5 million to relocate, re-equip and expand laboratory operations.
• Between the year 2003 and 2008, the revenues increased by five fold.
• In 2004, Philadelphia Business Journal recognized PCL as one of the best places to work in small businesses based on employee feedback.
• Sold the company in 2008 to Rosetta Genomics (ROSG), a global R&D biotech company leading the MicroRNA Revolution, realizing an IRR of 137%. (EBITDA X 27).

US

• Acquired financially distressed company in 2001.
• Invested more than $5million to transform the company into a multi-specialty national pathology company serving more than 500 providers in 30 States.
• Between the year 2001 and 2006, the revenues increased by ten fold.
• Company was recognized New Jersey’s fastest growing company for the years 2004, 05, 06 and was included in the Philadelphia 100 list for the year 2006.
• Sold the company in 2006 to Water Street Capital, a Chicago based Private Equity fund, realizing an IRR of 3,684%. (EBITDA X 8.3)

• Actively participated in company wide operations to bring operational efficiency and financial solvency.
• Helped the company right size by consolidating lab operations, shutting down non-productive patient service centers, spinning-off New Jersey division, negotiating corporate Integrity Agreement, and entering new market.
• Responsible for business planning, development, sales, marketing, strategic partner development.

Mba, Executive Mba

Md, Medicine